Inspire Medical Systems, Inc. $INSP Stock Position Lowered by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. has reduced its stock position in Inspire Medical Systems by 2.8% in the first quarter, now owning 287,892 shares valued at approximately $45.9 million.
• Inspire Medical Systems recently reported earnings of $0.45 per share, exceeding analysts' estimates, with quarterly revenue of $217.09 million, up 10.8% year-over-year.
• The company has authorized a $200 million stock repurchase program, indicating management's belief that the stock is undervalued.

Charles Schwab Investment Management Inc. reduced its stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 287,892 shares of the company's stock after selling 8,315 shares during the period. Charles Schwab Investment Management Inc. owned 0.98% of Inspire Medical Systems worth $45,855,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. SG Americas Securities LLC lifted its stake in shares of Inspire Medical Systems by 14.7% in the 1st quarter. SG Americas Securities LLC now owns 4,055 shares of the company's stock worth $646,000 after acquiring an additional 521 shares during the period. GAMMA Investing LLC lifted its stake in shares of Inspire Medical Systems by 253.7% in the 1st quarter. GAMMA Investing LLC now owns 573 shares of the company's stock worth $91,000 after acquiring an additional 411 shares during the period. New York State Teachers Retirement System lifted its stake in shares of Inspire Medical Systems by 132.7% in the 1st quarter. New York State Teachers Retirement System now owns 21,390 shares of the company's stock worth $3,407,000 after acquiring an additional 12,196 shares during the period. Bessemer Group Inc. lifted its stake in shares of Inspire Medical Systems by 1.7% in the 1st quarter. Bessemer Group Inc. now owns 7,183 shares of the company's stock worth $1,145,000 after acquiring an additional 123 shares during the period. Finally, Parallel Advisors LLC lifted its stake in shares of Inspire Medical Systems by 356.5% in the 1st quarter. Parallel Advisors LLC now owns 210 shares of the company's stock worth $33,000 after acquiring an additional 164 shares during the period. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Stock Performance

Shares of NYSE:INSP traded down $1.2860 during mid-day trading on Thursday, hitting $91.7640. The stock had a trading volume of 1,014,398 shares, compared to its average volume of 1,631,714. The company has a market cap of $2.71 billion, a PE ratio of 53.04, a P/E/G ratio of 2.90 and a beta of 1.22. Inspire Medical Systems, Inc. has a 12-month low of $73.92 and a 12-month high of $225.00. The company's 50 day moving average is $118.18 and its 200-day moving average is $145.50.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.22 by $0.23. The business had revenue of $217.09 million during the quarter, compared to the consensus estimate of $214.50 million. Inspire Medical Systems had a net margin of 6.17% and a return on equity of 10.38%. The firm's quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.32 EPS. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. On average, equities research analysts predict that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems announced that its Board of Directors has approved a stock buyback plan on Monday, August 11th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to reacquire up to 8.6% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on INSP shares. Lake Street Capital set a $150.00 price target on shares of Inspire Medical Systems and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Wall Street Zen lowered shares of Inspire Medical Systems from a "buy" rating to a "hold" rating in a research note on Saturday, July 26th. Piper Sandler cut their target price on shares of Inspire Medical Systems from $233.00 to $150.00 and set an "overweight" rating for the company in a research note on Tuesday, August 5th. JPMorgan Chase & Co. lowered shares of Inspire Medical Systems from an "overweight" rating to a "neutral" rating and cut their target price for the company from $195.00 to $110.00 in a research note on Tuesday, August 5th. Finally, Wells Fargo & Company cut their target price on shares of Inspire Medical Systems from $174.00 to $101.00 and set an "equal weight" rating for the company in a research note on Tuesday, August 5th. Seven analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $165.62.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.